Turnaround times
The quoted turnaround time is from sample receipt in the laboratory, to results authorisation in the Laboratory Information Management system. The times do not include transport of specimen to the laboratory or the administrative process to print and post/email reports. Service users must allow for transport and reporting time when ordering tests.
Clinical background:
C-peptide is formed as a by-product of the processing of insulin in the pancreatic ß cell. Proinsulin is cleaved to form equimolar amounts of mature insulin and c-peptide which are released into the circulation. So called because it connects the A and B chains of insulin in the proinsulin molecule, c-peptide is a single chain of 31 amino acids (Mol Wt. 3020 D). Because c-peptide has a longer half-life than insulin (2-5 times), higher concentrations of C-peptide persist in the peripheral circulation, and these levels fluctuate less than insulin. For these reasons, c-peptide concentrations may reflect pancreatic insulin secretion more reliably than the level of insulin itself.
C-peptide measurement may be used for the following clinical applications:
Investigation of hypoglycaemia (alongside insulin)
Assessment of beta cell function to distinguish between type 1 and type 2 diabetes or to assess the requirement for progression to insulin therapy in type 2 diabetes.
As a marker for residual endocrine pancreatic function after pancreatectomy. It may also be used to monitor the progress of pancreas or islet cell transplantation.
Specimen container paediatric:
Serum or plasma (LiHep or EDTA)
Specimen container adult:
Serum or plasma (LiHep or EDTA)
Minimum volume paediatric:
1 mL blood
Minimum volume adult:
1 mL blood
Special requirements:
Samples should be separated within 6 hours of sampling.
Also send glucose sample (fluoride/oxalate).
Sample stability:
Unseparated: 6 hours
Separated:3 days at 2-8°C, 2 months at -20°C
Transport requirements :
External locations: send as frozen serum/plasma.
Internal samples: send unseparated at ambient temperature to be received within 6 hours of sampling.
Interpretation:
When samples are taken during a hypoglycaemic episode, insulin and c-peptide concentrations that are not appropriately suppressed are consistent with endogenous hyperinsulinism. When insulin is elevated in the presence of suppressed c-peptide concentrations, this may indicate exogenous insulin administration (the insulin assay used in Newcastle has broad specificity and detects commonly used insulin analogues).
Measurement of c-peptide may be useful in the classification of type 1/type 2 diabetes where there is uncertainty. Utility is greatest 3-5 years after diagnosis when persistence of substantial c-peptide production suggests type 2 or monogenic diabetes. During the first 3-5 years there is considerable overlap in c-peptide concentrations between type 2 and type 1 diabetes, however undetectable c-peptide in the context of diabetes is consistent with insulin deficiency.
As the kidney is the major site for C-peptide metabolism, patients with severe renal insufficiency may have abnormally high circulating C-peptide levels.
Reference ranges:
Healthy adult fasting reference range: 0.34-1.80 nmol/L
(note that interpretation of insulin/c-peptide depends on prevailing plasma glucose concentrations and fasting status)
Factors affecting result:
N.B. Heterophilic antibodies can interfere with immunoassays.
Other info:
EDTA and LiHep plasma also suitable